• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Identifying a maximum tolerated contour in two-dimensional dose finding.在二维剂量探索中确定最大耐受轮廓。
Stat Med. 2017 Jan 30;36(2):242-253. doi: 10.1002/sim.6918. Epub 2016 Feb 22.
2
Designs for phase I trials in ordered groups.有序组中I期试验的设计。
Stat Med. 2017 Jan 30;36(2):254-265. doi: 10.1002/sim.7133. Epub 2016 Sep 14.
3
A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.一种用于癌症I期临床试验中使用药物组合估计最大耐受剂量曲线的贝叶斯自适应设计。
Stat Med. 2017 Jan 30;36(2):280-290. doi: 10.1002/sim.6961. Epub 2016 Apr 7.
4
A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.一种为I期临床试验的贝叶斯模型平均连续重新评估法指定骨架的默认方法。
Stat Med. 2017 Jan 30;36(2):266-279. doi: 10.1002/sim.6941. Epub 2016 Mar 16.
5
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.在非同步给药的双药一期试验中对半归因毒性进行建模。
Stat Med. 2017 Jan 30;36(2):225-241. doi: 10.1002/sim.6912. Epub 2016 Feb 19.
6
Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.基于区域和剂量结果的两阶段方法用于双药联合的I/II期试验。
J Biopharm Stat. 2018;28(6):1025-1037. doi: 10.1080/10543406.2018.1434190. Epub 2018 Feb 8.
7
A design for phase I trials in completely or partially ordered groups.完全或部分有序组中I期试验的一种设计。
Stat Med. 2017 Jul 10;36(15):2323-2332. doi: 10.1002/sim.7295. Epub 2017 Apr 6.
8
Performance of toxicity probability interval based designs in contrast to the continual reassessment method.基于毒性概率区间的设计与连续重新评估方法的性能对比。
Stat Med. 2017 Jan 30;36(2):291-300. doi: 10.1002/sim.7043. Epub 2016 Jul 19.
9
Sequential monitoring of Phase I dose expansion cohorts.对I期剂量扩展队列进行序贯监测。
Stat Med. 2017 Jan 30;36(2):204-214. doi: 10.1002/sim.6894. Epub 2016 Feb 7.
10
Designs for single- or multiple-agent phase I trials.单药或多药I期试验的设计。
Biometrics. 2004 Sep;60(3):661-9. doi: 10.1111/j.0006-341X.2004.00215.x.

引用本文的文献

1
Concurrent dose-finding of a novel cancer drug with and without a second agent.一种新型癌症药物在联合或不联合第二种药物情况下的同步剂量探索。
J Clin Transl Sci. 2023 May 10;7(1):e126. doi: 10.1017/cts.2023.542. eCollection 2023.
2
Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.I期肿瘤药物联合试验新设计的准确性和安全性
Stat Biopharm Res. 2022;14(3):270-282. doi: 10.1080/19466315.2022.2081602. Epub 2022 Aug 2.
3
AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.AAA：用于双药剂量探索试验中确定最佳剂量组合的三重自适应贝叶斯设计
J R Stat Soc Ser C Appl Stat. 2019 Feb;68(2):385-410. doi: 10.1111/rssc.12291. Epub 2018 Jun 13.
4
Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.使用细胞毒性药物连续剂量组合的I-II期癌症临床试验的两阶段设计。
J R Stat Soc Ser C Appl Stat. 2019 Jan;68(1):235-250. doi: 10.1111/rssc.12294. Epub 2018 Jun 22.
5
Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.在早期癌症I期试验中使用条件连续重新评估法进行联合用药的剂量探索
J Biom Biostat. 2017;8(6). doi: 10.4172/2155-6180.1000381. Epub 2017 Nov 27.
6
Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.允许不良事件归因存在不确定性的I期设计。
J R Stat Soc Ser C Appl Stat. 2017 Nov;66(5):1015-1030. doi: 10.1111/rssc.12195. Epub 2016 Nov 7.
7
A design for phase I trials in completely or partially ordered groups.完全或部分有序组中I期试验的一种设计。
Stat Med. 2017 Jul 10;36(15):2323-2332. doi: 10.1002/sim.7295. Epub 2017 Apr 6.

本文引用的文献

1
Bayesian optimal interval design for dose finding in drug-combination trials.药物联合试验中剂量探索的贝叶斯最优区间设计
Stat Methods Med Res. 2017 Oct;26(5):2155-2167. doi: 10.1177/0962280215594494. Epub 2015 Jul 15.
2
A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.一种适用于异质性群体的I/II期适应性设计及其在立体定向体部放射治疗试验中的应用。
Pharm Stat. 2015 Jul-Aug;14(4):302-10. doi: 10.1002/pst.1686. Epub 2015 May 11.
3
Phase I trial design for drug combinations with Bayesian model averaging.采用贝叶斯模型平均法的药物联合方案的I期试验设计
Pharm Stat. 2015 Mar-Apr;14(2):108-19. doi: 10.1002/pst.1668. Epub 2015 Jan 13.
4
A product of independent beta probabilities dose escalation design for dual-agent phase I trials.用于双药一期试验的独立贝塔概率剂量递增设计的一个产物。
Stat Med. 2015 Apr 15;34(8):1261-76. doi: 10.1002/sim.6434. Epub 2015 Jan 29.
5
Bridging Solutions in Dose Finding Problems.剂量探索问题中的桥接解决方案
Stat Biopharm Res. 2014 May 1;6(2):185-197. doi: 10.1080/19466315.2014.906365.
6
A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.一种基于逻辑模型的药物联合临床试验的贝叶斯剂量探索设计。
Pharm Stat. 2014 Jul-Aug;13(4):247-57. doi: 10.1002/pst.1621. Epub 2014 May 15.
7
Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.使用有超量控制的条件递增法在癌症 I 期临床试验中进行药物组合的剂量探索。
Stat Med. 2014 Sep 28;33(22):3815-29. doi: 10.1002/sim.6201. Epub 2014 May 13.
8
A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.用于双主体I期试验的广义连续重新评估方法。
Stat Biopharm Res. 2013 Jan 1;5(2):105-115. doi: 10.1080/19466315.2013.767213.
9
Dose-finding trial designs for combination therapies in oncology.肿瘤学联合疗法的剂量探索试验设计。
J Clin Oncol. 2014 Jan 10;32(2):65-7. doi: 10.1200/JCO.2013.52.9198. Epub 2013 Dec 9.
10
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.Neratinib 联合替西罗莫司治疗人表皮生长因子受体 2 依赖性和其他实体瘤患者的 I 期研究。
J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.

在二维剂量探索中确定最大耐受轮廓。

Identifying a maximum tolerated contour in two-dimensional dose finding.

作者信息

Wages Nolan A

机构信息

Translational Research and Applied Statistics, Public Health Sciences, University of Virginia, Charlottesville, 22908, VA, U.S.A.

出版信息

Stat Med. 2017 Jan 30;36(2):242-253. doi: 10.1002/sim.6918. Epub 2016 Feb 22.

DOI:10.1002/sim.6918
PMID:26910586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4993696/
Abstract

The majority of phase I methods for multi-agent trials have focused on identifying a single maximum tolerated dose combination (MTDC) among those being investigated. Some published methods in the area have been based on the notion that there is no unique MTDC and that the set of dose combinations with acceptable toxicity forms an equivalence contour in two dimensions. Therefore, it may be of interest to find multiple MTDCs for further testing for efficacy in a phase II setting. In this paper, we present a new dose-finding method that extends the continual reassessment method to account for the location of multiple MTDCs. Operating characteristics are demonstrated through simulation studies and are compared with existing methodology. Some brief discussion of implementation and available software is also provided. Copyright © 2016 John Wiley & Sons, Ltd.

摘要

多药物试验的大多数I期方法都集中在在所研究的剂量组合中确定单一的最大耐受剂量组合（MTDC）。该领域已发表的一些方法基于这样的观念，即不存在唯一的MTDC，并且具有可接受毒性的剂量组合集在二维空间中形成一个等效轮廓。因此，在II期试验中寻找多个MTDC以进一步测试疗效可能是有意义的。在本文中，我们提出了一种新的剂量寻找方法，该方法扩展了连续重新评估方法以考虑多个MTDC的位置。通过模拟研究展示了操作特征，并与现有方法进行了比较。还提供了关于实施和可用软件的一些简要讨论。版权所有© 2016约翰威立父子有限公司。